Choose Your Country or Region

Minocycline HCl

Name: Minocycline HCl
Brand: Selleck Chemicals
SKU: S4226
Rating: 5 (35 reviews)

Synonyms: CL 59806

Catalog No.S4226 Purity:99.94%

Minocycline HCl is the most lipid soluble and most active tetracycline antibiotic, binds to the 30S ribosomal subunit, preventing the binding of tRNA to the mRNA-ribosome complex and interfering with protein synthesis.

Minocycline HCl Chemical Structure

CAS No. 13614-98-7

Purity & Quality Control

Batch: Purity: 99.94%

99.94

Minocycline HCl Related Products

Related Products	Nanchangmycin Fusidine Sitafloxacin Hydrate Gamithromycin Tildipirosin Spiramycin Nadifloxacin	Click to Expand
Related Compound Libraries	Anti-infection Compound Library Antibiotics compound Library Antiviral Compound Library Anti-parasitic Compound Library Gut Microbial Metabolite Library	Click to Expand

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
Jurkat cells	Cell viability assay	10-200 µM	24 h	reduces cell viability and induces DNA fragmentation and dissipation of the mitochondrial membrane potential in Jurkat cells but is harmless to human peripheral blood lymphocyte cells (hPBLCs)	29625165
hPBLCs	Cell viability assay	10-200 µM	24 h	reduces cell viability and induces DNA fragmentation and dissipation of the mitochondrial membrane potential in Jurkat cells but is harmless to human peripheral blood lymphocyte cells (hPBLCs)	29625165
Click to View More Cell Line Experimental Data

Biological Activity

Description	Minocycline HCl is the most lipid soluble and most active tetracycline antibiotic, binds to the 30S ribosomal subunit, preventing the binding of tRNA to the mRNA-ribosome complex and interfering with protein synthesis.

In vitro
In vitro	Minocycline is a second-generation tetracycline used in humans, which effectively crosses the blood−brain barrier. It inhibits the activity of caspase-1, caspase-3, inducible form of nitric oxide synthetase (iNOS) and p38 mitogen-activated protein kinase (MAPK). After experimental ischemia, minocycline inhibits caspase-1 and inducible nitric oxide synthetase (iNOS) upregulation, and decreases infarct size. Minocycline inhibits mitochondrial permeability-transition-mediated cytochrome c release. Minocycline-mediated inhibition of cytochrome c release is demonstrated in vivo, in cells, and in isolated mitochondria. ^[2]
Cell Research	Cell lines	OVCAR-3, SKOV-3 and A2780 cells
	Concentrations	IC50 values of 62.0, 56.1 and 59.5 μM, respectively
	Incubation Time	72 h
	Method	Cells were treated with various concentrations of drug for 72 h.
Experimental Result Images	Methods	Biomarkers	Images	PMID
	Western blot	IL-6Rα / gp130 p-STAT3 / STAT3 / Mcl-1 / p-ERK / ERK		23593315
	Immunofluorescence	p-STAT3 STAT3		23593315
	Growth inhibition assay	Cell viability		27555377

In Vivo

In vivo

Minocycline is a semi-synthetic tetracycline derivative which is well absorbed and distributed in body tissues and is suitable for twice daily administration. Minocycline's effects are related to the inhibition of protein synthesis. Although minocycline's broader spectrum of activity, compared to other members of the group, includes activity against Neisseria meningitidis, its use as a prophylaxis is no longer recomended because of side effects (dizziness and vertigo). ^[1]

Minocycline is remarkable neuroprotective qualities in models of cerebral ischaemia, traumatic brain injury, and Huntington's and Parkinson's disease. The neuroprotective action of minocycline may include its inhibitory effect on 5-lipoxygenase, an inflammatory enzyme associated with brain aging. ^[3]

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2024-05-22)
NCT05605366	Not yet recruiting	Sickle Cell Disease\|Cognitive Impairment\|Cognitive Decline\|Cognitive Change\|Cognitive Dysfunction\|Cognitive Deficit\|Neuroinflammatory Response	University of Cincinnati	June 1 2024	Phase 1
NCT05861258	Recruiting	Mycobacterium Avium Complex Pulmonary Disease	Radboud University Medical Center	May 8 2023	Phase 2
NCT05630534	Not yet recruiting	Intracerebral Hemorrhage	Second Affiliated Hospital School of Medicine Zhejiang University\|The Fourth Affiliated Hospital of Zhejiang University School of Medicine\|The Second Affiliated Hospital of Jiaxing University	January 1 2023	Phase 1

References

[4] Pourgholami MH, et al. Gynecol Oncol. 2012 May;125(2):433-40.

+ Expand

Chemical Information & Solubility

Molecular Weight	493.94	Formula	C₂₃H₂₇N₃O₇.HCl
CAS No.	13614-98-7	SDF	Download Minocycline HCl SDF
Smiles	CN(C)C1C2CC3CC4=C(C=CC(=C4C(=C3C(=O)C2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C.Cl
Storage (From the date of receipt)	3 years-20°Cpowder	Storage of Stock Solutions Aliquot the stock solutions to avoid repeated freeze-thaw cycles	1 year-80°Cin solvent
Storage (From the date of receipt)	3 years-20°Cpowder		1 month-20°Cin solvent

In vitro
Batch:

Water : 6 mg/mL

DMSO : Insoluble ( Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : Insoluble

Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.

In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):